-
Article
Open AccessA randomized, controlled phase II trial of neoadjuvant ado-trastuzumab emtansine, lapatinib, and nab-paclitaxel versus trastuzumab, pertuzumab, and paclitaxel in HER2-positive breast cancer (TEAL study)
Neoadjuvant dual human epidermal growth factor receptor (HER2) blockade with trastuzumab and pertuzumab plus paclitaxel leads to an overall pathologic complete response (pCR) rate of 46%. Dual HER2 blockade wi...
-
Article
Open AccessAntitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells
Develo** novel strategies against treatment-resistant triple negative breast cancer (TNBC) cells remains a significant challenge. The ErbB family, including epidermal growth factor receptor (EGFR), plays key...
-
Article
Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients
Due to the spatial and temporal genomic heterogeneity of breast cancer, genomic sequencing obtained from a single biopsy may not capture the complete genomic profile of tumors. Thus, we propose that cell-free ...
-
Article
Open AccessInhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer
Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer with no effective targeted therapy. Inducible nitric oxide synthase (iNOS) is associated with poor survival in patients with breast c...
-
Article
Open AccessErratum to: Dual HER2 blockade: preclinical and clinical data
No abstract.
-
Article
Open AccessDual HER2 blockade: preclinical and clinical data
The estrogen receptor and human epidermal growth factor receptor (HER) signaling pathways are the dominant drivers of cell proliferation and survival in the majority of human breast cancers. Not surprisingly, ...
-
Article
Open AccessCharacterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells
Since the first suggestion of prospectively identifiable cancer stem cells in solid tumors, efforts have been made to characterize reported cancer stem cell surrogates in existing cancer cell lines, and cell l...
